digipharm®
Home •  Site Map  •  Research  •  Reports  •  International Experts  •  Music Preparations  •  Fundamentals  •  News  •  Questions  •  Shop
digipharm®
peter huebner • micro music laboratories
M E D I C A L   R E S O N A N C E   T H E R A P Y   M U S I C®
R E D U C T I O N   O F   P S Y C H O – P H Y S I O L O G I C A L   M A N I F E S T A T I O N S   O F   S T R E S S

SCIENTIFIC RESEARCH

Research Fields Summary

Headaches

Migraine

Sleep Disorders

Pains

Neurodermatitis

Psoriasis

Medication Consumption

Dermatology

Dispersion of Stress

Faster Recovery

Mental Distress / Fear

Dizziness

Cardiovascular System

Hormone / Immune System

The Mental State

Operations

Radiation Sickness

ENT

Multiple Sclerosis

Gerontology

Diabetes

Cerebral & Nervous System

Mental & Sensory Abilities

Pediatrics

Pregnancy & Birth

Gynecology

Epilepsy

Concentration / Memory

Courage to Face Life

Creativity

Harmony

Mother & Child

Neurophysiological &
Sensory Disorders

Relaxation

Vital Energy

 

 






Scientific Studies and Clinical Observations – Summary
Women’s Health
Pregnancy
  • Calming of the child inside the mother’s body during labor.

  • Taking of fetal heart activity out of the danger zone to a very satisfactory condition.

  • Significant improvement in the hormone status in pregnant women with somatic disorders leading to a significant increase in the well-being of mother and child, compared to only minor improvement in the control group.

  • Improvement of the kariopicnotic index (KPI) in risk pregnancies: in the Medical Resonance Therapy Music® group the KPI first fell to 10-12%, after 6 days to 7-8%, after 9 days to 6-8%. In the control group it first fell to 14-17%, after 6 days to 11-13%, after 9 days to 9-10% – so significantly less. The fall in the KPI shows a significant improvement in the course of the pregnancy.

  • Significant reduction in the number of premature births – from 14% down to 6,2% – since the introduction of treatment with Medical Resonance Therapy Music® for pregnant women facing the risk of miscarriage.

  • Faster normalization of excessively high blood pressure (reduction of 15-20 mmHg) in pregnant women with mild gestosis (OPH syndrome) than in the medication group.

  • Dispersion of the clinical risk characteristics in pregnant women with a threat of miscarriage:
    after 2-3 days there were no longer any clinical risk characteristics in 60% of the women, in 100% after 5-7 days. In the control group: the clinical risk characteristics had disappeared in 70% after 7-10 days, in 30% there was no complete dispersion of the risk characteristics.

  • Improvement of the general mental state in women with a mild gestosis (OPH-syndrome): For 7-10 days 13 women listened to the Medical Resonance Therapy Music® in the morning and after lunch and had no other therapy during these days. In 10 of the 13 women (77%) the treatment with the music caused a clear improvement of the mental state.

  • Calming of the fetus during labor: Acceleration and deceleration of fetal heart beat reduced – the fetus was calmed.

  • Reducing sleep disorders in pregnant women with somatic disorders in the last month of pregnancy: Before starting with the treatment, the frequency of sleep disorders was 86%, after the conventional treatment and the additional application of the Medical Resonance Therapy Music® it was only 7%. In the control group: prior to treatment 50%, after treatment an increase to 80%.

  • Normalization of sleep in 61% of pregnant women, compared to 30% in the medication group.

  • Improvement in the hormone status in pregnant women with somatic disorders: increase in the placentalactogen content from 217.5 nmol/l to 274.9 nmol/l and of the estriol level from 80.0 ƒÊ mol/24 hours to 103.3 ƒÊ mol/24 hours, leading to an improvement in the well-being of the mother and child.

  • Improvement in the fetal heart activity in pregnant women with gestosis (OPH syndrome): 14% faster than in the control group: the cardiotocogram showed a normalization of the condition of the fetus in 86% of the studies. After only 6 treatments the number of accelerations and the variability had increased and treatment could be completed after 12 days. In the control group normalization first occurred after 9-10 days and the entire treatment required 14 days.

  • Faster breakdown of the protein content in the urine of pregnant women with gestosis (OPH syndrome).

  • Improvement of sleep in 77% of the pregnant women with a mild form of gestosis (OPH syndrome). Reducing the frequency of sleep disorders from 86% to 7%. In the control group an increase from 50% to 80%.

  • Improvement in the hormone status in risk pregnancies: reduction of the cortisol level by 36% (double compared to that in the control group) coupled with a simultaneous increase in the progesterone level by 100% (almost four times as much as in the control group). The lowering of the cortisol level minimizes the stress risk-factor threatening the pregnancy, whilst the doubling of the progesterone increases the well-being of mother and child.

  • Reducing the frequency of headache attacks in pregnant women from 73% to 20%. In the control group there was an increase from 60% to 70%.

  • Improvement of restless and melancholy emotional states in pregnant women under threat of miscarriage in the first trimester of pregnancy: Evaluating the MMPI a healing effect of the MRT-Music® could be documented in 14 out of 15 pregnant women. The improvement in the mood and the general state stood at 87% of the reports. At the end of the treatment with the MRT-Music® the mental state of 69,2% of the women was normal again; there was no incidence of a deterioration in the mental state. The results of the control group: in 40% a complete normalization, in 40% a further aggravation of the state.

  • Normalization of the immune status in 56% of pregnant women from a group under the threat of miscarriage. In the control group the immune status normalized in 46% of the pregnant women.

  • Reduction of mental manifestations of stress: reduction of the emotional stress in pregnant women with somatic disorders by 47%, compared to no reduction of stress in the control group.

  • Taking of fetal heart activity out of the danger zone up to a level of 9.2 on the Krebs’ scale, which indicates a very satisfactory fetal condition.

  • Faster normalization of high blood pressure in pregnant women than in a control group receiving hypotonic and sedative medicine.

  • Shorter stay in hospital:
    Faster recovery in pregnant women under threat of miscarriage in the first trimester of pregnancy – the women could leave the hospital successfully treated already after 9-11 days: by 35% quicker than the patients in the control group.

  • Faster recovery in high-risk pregnancies with gestosis (OPH syndrome): in this group treatment could be completed 14% faster than in the control group.

  • Faster recovery of pregnant women at risk with a mild form of gestosis (OPH-syndrome): Improvement in fetal heart activity: 20 - 30% faster than in the control group.
    The cardiotocogram showed a normalization of the condition of the fetus in 86% of the studies. This was also subjectively confirmed by the mothers-to-be who felt better and better. After only 6 treatments the number of accelerations and the variability of fetal heart beat had improved, documenting an improved function of the fetal-placental system. The treatment in the MRT-Music® group could be completed after 12 days, normalization in the control group first occurred after 9-10 days and the entire treatment required 14 days – that is, the recovery of the MRT-Music® group was 14% faster.

  • Improvement of sleep in 77% of the pregnant women with a mild form of gestosis (OPH syndrome). Reducing the frequency of sleep disorders from 86% to 7%. In the control group an increase from 50% to 80%.
 


  Pregnancy and Birth   For this indication please use the program:

PREGNANCY & BIRTH
 
  If you want to look at the studies in detail, please visit:
SCIENTIFIC STUDIES & CLINICAL OBSERVATIONS – COMPLETE STUDIES
With kind permission of AAR EDITION INTERNATIONAL
© 1998-  DIGIPHARM >